<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00181714</url>
  </required_header>
  <id_info>
    <org_study_id>2003-P-001313</org_study_id>
    <nct_id>NCT00181714</nct_id>
  </id_info>
  <brief_title>Prevention of Cigarette Smoking in Attention Deficit Hyperactivity Disorder (ADHD) Youth With Concerta</brief_title>
  <official_title>Prevention of Cigarette Smoking in ADHD Youth With Concerta</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ortho-McNeil Janssen Scientific Affairs, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will consist of a six-week open-label treatment period with an extended duration
      methylphenidate (OROS MPH) followed by subsequent monthly visits for 24 months in a large
      sample of youths aged 12-17 who meet Diagnostic and Statistical Manual of Mental Disorders,
      Fourth Edition (DSM-IV) criteria for ADHD.

      The researchers hypothesize that OROS MPH treatment will be associated with low rates of
      cigarette smoking in ADHD youth.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cigarette Smoking</measure>
    <time_frame>24 months</time_frame>
    <description>Cigarette smoking was assessed by youth self report using a modified version of the Fagerstrom Tolerance Questionnaire (FTQ)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">203</enrollment>
  <condition>ADHD</condition>
  <arm_group>
    <arm_group_label>OROS MPH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm- open treatment with extended duration methylphenidate (OROS MPH)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylphenidate HCl (Concerta)</intervention_name>
    <description>OROS MPH will be openly prescribed to a maximum of 1.5 mg/kg/day (maximum 126 mg/day). Doses will be titrated according to clinical assessment of efficacy and tolerability.</description>
    <arm_group_label>OROS MPH</arm_group_label>
    <other_name>Concerta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adolescent outpatients between 12 to 17 years of age (inclusive).

          2. Subjects with the DSM-IV diagnosis of ADHD, as manifested in the clinical evaluation
             and confirmed by structured interview.

          3. Subjects with sufficient current ADHD symptoms to warrant treatment, as measured by a
             Clinical Global Impression Severity Scale (CGI-S) score of greater than or equal to 4
             (moderately ill); OR subjects already on Concerta who are judged to be responders (CGI
             of 1 or 2) and who tolerate treatment well.

        Exclusion Criteria:

          1. Any serious or unstable medical illness including hepatic, renal, gastroenterologic,
             respiratory, cardiovascular (including ischemic heart disease, hypertension),
             endocrinologic, neurologic, immunologic, or hematologic disease.

          2. Clinically significant abnormal baseline laboratory values

          3. History of seizures

          4. Active tic disorder

          5. Pregnant or nursing females

          6. Mental retardation (intelligence quotient [IQ] &lt; 75)

          7. Organic brain disorder

          8. Eating disorders

          9. Psychosis

         10. Current bipolar disorder (current episode)

         11. Current depression &gt; mild (CGI-S &gt; 3)

         12. Current anxiety &gt; mild (CGI-S &gt; 3)

         13. Substance abuse or dependence within the past 2 months

         14. Recent change in non-monoamine oxidase inhibitor (MAOI) antidepressants (&lt; 3 months)

         15. Recent change in benzodiazepines (&lt; 3 months)

         16. Concerta non-responder
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Biederman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <results_first_submitted>January 5, 2012</results_first_submitted>
  <results_first_submitted_qc>January 5, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 7, 2012</results_first_posted>
  <last_update_submitted>May 2, 2013</last_update_submitted>
  <last_update_submitted_qc>May 2, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 7, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Joseph Biederman, MD</investigator_full_name>
    <investigator_title>Chief, Clinical and Research Programs in Pediatric Psychopharmacology and Adult ADHD</investigator_title>
  </responsible_party>
  <keyword>cigarette smoking</keyword>
  <keyword>ADHD</keyword>
  <keyword>adolescents</keyword>
  <keyword>Concerta</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylphenidate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>OROS-Methylphenidate</title>
          <description>Youth ages 12-17 years with DSM-IV ADHD, treated with open-label OROS-MPH.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Signed Consent/Enrolled</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="203"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Began Treatment With OROS-MPH</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>OROS-Methylphenidate</title>
          <description>Youth ages 12-17 years with DSM-IV ADHD, treated with open-label OROS-MPH.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="154"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.3" spread="1.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cigarette Smoking</title>
        <description>Cigarette smoking was assessed by youth self report using a modified version of the Fagerstrom Tolerance Questionnaire (FTQ)</description>
        <time_frame>24 months</time_frame>
        <population>Clinical trial subjects included in this analysis included those adolescents who took at least one dose of OROS MPH following baseline assessment (N=154), with the last observation carried forward (LOCF) for subjects who did not complete the full study schedule of 24 months</population>
        <group_list>
          <group group_id="O1">
            <title>OROS-Methylphenidate</title>
          </group>
        </group_list>
        <measure>
          <title>Cigarette Smoking</title>
          <description>Cigarette smoking was assessed by youth self report using a modified version of the Fagerstrom Tolerance Questionnaire (FTQ)</description>
          <population>Clinical trial subjects included in this analysis included those adolescents who took at least one dose of OROS MPH following baseline assessment (N=154), with the last observation carried forward (LOCF) for subjects who did not complete the full study schedule of 24 months</population>
          <units>percent</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>OROS-Methylphenidate</title>
          <description>Youth ages 12-17 years with DSM-IV ADHD, treated with open-label OROS-MPH.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>viral illness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>leg fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>unintentional carbon monoxide poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>spontaneous pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.001</frequency_threshold>
        <default_vocab>insomnia</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>ear pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>stomach ache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>allergies</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>jumbled thoughts</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>cold symptoms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>congestion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>cranky</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>decreased appetite</sub_title>
                <counts group_id="E1" events="27" subjects_affected="19" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>decreased energy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>dull</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>foot pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="25" subjects_affected="14" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>heart racing</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>hoarse voice</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>hot/cold flashes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>hyper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>inflamed adenoids</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>initial insomnia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>irritable</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>jittery</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>knee pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>lightheadedness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>low interest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>moody</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>nose bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>orthodontic pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>otitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>phinorhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>rapid pulse</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>runny nose</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>sad</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>shoulder pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>sore throat</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>teary</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>tense</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>toothache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>twisted ankle pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>dental infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>infected ingrown tonail</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>deer tick bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>hand lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>TMJ</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>costosternal muscle strain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>muscle aches</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>pain extension in bilateral arms/legs</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>increased urination</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>menstrual cramps</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>asthma attack</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>tight breathing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>acne</sub_title>
                <counts group_id="E1" events="8" subjects_affected="4" subjects_at_risk="154"/>
              </event>
              <event>
                <sub_title>rash (poison ivy)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The main limitation of this report stems from its uncontrolled, open-label design. Thus, we cannot assert a causal relationship between lower smoking rates and OROS MPH prescription.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Paul Hammerness, MD</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-503-1063</phone>
      <email>phammerness@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

